|
Epilepsy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Compared with the epilepsy group, PTA increased the levels of GABA (both doses P<0.01) and GAD65 (mRNA, 800 mg/kg, P<0.01), and suppressed the levels of GAT-1 (mRNA, 800 mg/kg, P<0.01; 400 mg/kg, P<0.05), GABA-T (mRNA, both doses P<0.01), and GABA<sub>A</sub>R δ subunit (protein, 800 mg/kg, P<0.05) and γ2 subunit (protein, both doses P<0.01).
|
31093879 |
2020 |
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Neural specific antibodies commonly associated with autoimmune epilepsy include leucine-rich glioma-inactivated protein 1 (LGI1), N-methyl-D-aspartate receptor (NMDA-R), and glutamic acid decarboxylase 65 (GAD65) IgG.
|
31240596 |
2019 |
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Since GAD65 is intracellularly located and associated with type 1 diabetes mellitus and different clinical neurological phenotypes such as CA, stiff-person syndrome, and epilepsy, some researchers have argued that anti-GAD65 Abs have no pathogenic roles.
|
30343467 |
2019 |
|
Epilepsy
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A high level of GAD65-Ab was found in cerebral spinal fluid, confirming a diagnosis of epilepsy associated with GAD65-Ab encephalitis.
|
31649008 |
2019 |
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
BEFREE |
The patient was diagnosed with GAD65 antibody-associated autoimmune epilepsy.
|
29905150 |
2018 |
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
BEFREE |
An institutional database search identified patients with elevated serum GAD65 antibodies and a clinical diagnosis of autoimmune epilepsy who had undergone brain MRI.
|
29353399 |
2018 |
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
BEFREE |
Unlike other immune-mediated epilepsies, antiglutamic acid decarboxylase 65 (GAD65) antibody-mediated epilepsy is often poorly responsive to antiepileptic drugs (AEDs) and only moderately responsive to immune therapy with steroids, intravenous immunoglobulin (IVIG), or plasma exchange (PLEX).
|
29433947 |
2018 |
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> There is scanty guidance in the literature on the management of patients with glutamic acid decarboxylase (GAD65) antibody associated autoimmune epilepsy (GAD-epilepsy).
|
30057567 |
2018 |
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
BEFREE |
GAD65 autoantibody characteristics in patients with co-occurring type 1 diabetes and epilepsy may help identify underlying epilepsy etiologies.
|
29636076 |
2018 |
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
BEFREE |
In contrast patients with seizures related to GAD65-antibodies (an intracellular antigen) frequently develop epilepsy and have suboptimal response to treatment (including surgery).
|
28234800 |
2017 |
|
Epilepsy
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
JNJ-26481585 significantly reversed the decrease of the GAD67/GAD65 both protein and mRNA levels, and the histone hypoacetylation of GABAergic neurons in epilepsy mice.
|
27220336 |
2016 |
|
Epilepsy
|
0.300 |
Biomarker
|
disease |
MGD |
|
|
|